Interventional Cardiology Devices – Market Insights – Asia Pacific

The Asia Pacific IC device market is bolstered by a growing CAD patient population, an increasing prevalence of complex lesions, enhanced access to treatment, a rising preference for minimally invasive procedures in CAD cases, and the advent of technologically advanced, premium-priced diagnostic and treatment devices that offer case-specific diagnosis and intervention for CAD cases of varying complexity. Going forward, the Asia Pacific IC device market is expected to expand moderately, driven by the growth in the coronary stent, balloon, and intravascular imaging and pressure guidewire segments.

This Medtech 360 Report provides comprehensive data and analysis on the state of the interventional cardiology device market in Asia Pacific from 2019 through 2033.

A number of flagship devices have launched in the highly competitive DES market.

How have the market dynamics changed with new launches?

What competitive strategies competitors are deploying to gain share in this market?

Which DES are in the pipeline to enter the market over the forecast period?

New technologies are changing the way complex PCIs are diagnosed and treated.

What is the impact of the latest generation of alternative coronary physiology modalities, such imaging-based FFR_angio and FFR_CT, on existing intravascular imaging technologies, including traditional FFR and IVUS?

What is the expected impact of emerging balloon-based technologies, such as DCBs?

How is the BRS segment performing in the Asia Pacific market?

How are new clinical trials impacting IC device segments, procedures, competitors, and products?

How is the uptake of noninvasive imaging technologies in the Asia Pacific IC device market?

Device ASP trends will play a significant role in determining market growth through 2033.

How will ASP trends vary by country? What factors will contribute to these differences?

How will government-driven pricing pressures and increasing competition affect ASPs, and which product segments will be most impacted?

The introduction of intravascular lithotripsy has revolutionized the treatment of calcified coronary lesions and vessel preparation prior to stenting.

How has the commercialization of coronary lithotripsy impacted the use of other products used in the interventional cardiology space?

How is reimbursement changing for coronary lithotripsy, and how will this affect the adoption of this technology?